Cell Line Development Market size worth over $9.8 Bn by 2026

Cell Line Development Market size is set to reach USD 9.8 billion by 2026, according to a new research report by Global Market Insights, Inc.
 

Growing burden of chronic and infectious diseases worldwide will drive the market growth. According to the WHO, cancer is the second leading cause of mortality globally, accounting for more than 9.5 million deaths in 2018. Growing incidences of cancer leading to rise in vaccine production and increasing awareness regarding monoclonal antibodies will propel the industry growth. Growing demand for cell line-based vaccines for hepatitis A, rubella, varicella, zoster, rotavirus and smallpox, produced using human cell lines, will further favor cell line development industry progress over the forecast period.

 

Request Sample Buy NowInquiry Before Buying

 

Innovation and advances in the cell line development technologies to foster the cell line development market growth

Technological innovations in the field of cell line development for faster and higher production of cell lines will prove beneficial for the market expansion. Availability of automated screening methods, improved expression systems, advanced monitoring processes, enriched medias and disposable equipment, will enhance the capabilities of cell line development practices. Furthermore, advancements in the biotechnology field and patent expiration of blockbuster biologics will increase the need for innovation, thereby, up surging product demand over the coming years.
 

Cell Line Development Market By Region

Get more details on this report - Request Free Sample PDF
 

Requirement of safety equipment in research laboratories to prevent cell culture contamination will spur the market revenue

Based on products, the cell line development market is segmented into reagents & media, equipment, accessories & consumables. The equipment segment was valued around USD 1.7 billion in 2019 and will show significant growth over the analysis period. Segment growth is attributed to advancement in cell line development technologies for rapid development of recombinant protein therapeutic products as well as improvement in the speed and process for large scale cell line production.
 

Usage of safety equipment in cell culture laboratories including biosafety cabinets, enclosed containers and other engineering controls that are designed to eliminate or lessen the exposure to harmful substances in combination with primary barriers will favor the product demand. Growing adoption of advanced equipment for faster development of biosimilars and innovative products will thus, spur the market size.
 

Browse key industry insights spread across 200 pages with 166 market data tables & 10 figures & charts from the report, “Cell Line Development Market Size By Product (Reagents & Media, Equipment {Incubator, Centrifuge, Bioreactor, Storage Equipment, Microscope}, Accessories & Consumables), By Source (Mammalian, Non-Mammalian {Insects, Amphibians}), By Cell Line (Recombinant, Hybridomas, Continuous Cell Line, Primary Cell Line), By Application (Bioproduction, Drug Discovery, Toxicity Testing, Tissue Engineering, Research) Industry Analysis Report, Regional Outlook, Price Trends, Application Potential, Competitive Market Share & Forecast, 2020 – 2026” in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/cell-line-development-market-report
 

Application of non-mammalian cell lines in toxicology study will pave opportunities for market growth

The non-mammalian cell line source is projected to witness around 12% CAGR through 2026. Non-mammalian cell lines include plant cell culture, insect cell culture and bacterial yeast culture, that is typically grown as suspension culture in the liquid or solid medium known as callus culture. Widespread application of non-mammalian cell line systems in various research fields to study pathology, toxicology, activity assay, drug resistance and post-translational modification in proteins, will increase its demand during the forthcoming years.
 

Increasing patient preference towards regenerative medicine will escalate the market progression

Different types of cell lines include recombinant cell lines, continuous cell lines, hybridomas and primary cell lines. Hybridomas segment held over 25% cell line development market share in 2019 owing to growing adoption of this technology for large scale production of monoclonal antibodies. Monoclonal antibodies help in improving quality of life in patients suffering from autoimmune diseases, cancer and anti-inflammatory disorders.
 

Moreover, hybridoma technology offers advantage over other cell types such as combination of two different types of cells as well as continuous and large-scale production of pure antibodies. Increasing R&D investments for developing monoclonal antibodies for the treatment of critical health conditions will prove beneficial for the market expansion.
 

Tissue engineering is one of the fastest growing interdisciplinary research fields

Tissue engineering segment was valued around USD 600 million in 2019 and is anticipated to witness around 13.5% CAGR through 2026. Utilization of tissue engineering for development of biological substitutes to restore, maintain and improve damaged tissues is increasing over the recent years. Tissue engineering is preferred in various patient treatments including implantation of bladders, skin grafts, small arteries, trachea and cartilage. Increasing research on bone marrow mesenchymal stem cells, cord derived mesenchymal stem cells and embryonic stem cells will further fuel the market growth.
 

North America is the hotbed for cell line development and innovation in biologics

North America cell line development market dominated the global market in 2019 and is poised to exceed USD 3.3 billion by 2026. Regional market growth is attributed to growing demand for biologics and rising awareness among people regarding cell therapies such as use of monoclonal antibodies in cancer treatment. Surge in vaccine production and rapid advances in novel cell line development technologies will boost the regional market demand.
 

Furthermore, strong foothold of major industry players and rising investments in R&D activities will further drive the regional market growth during 2020 to 2026.
 

Large consumer base for cell line development products will offer several growth opportunities to the business players

Some of the major players operating in cell line development market share include Thermo Fisher Scientific, Wuxi AppTec, GE Healthcare, Lonza Group, Corning, Cobra Biologics, Sigma-Aldrich Corporation, Vista Biologics, Patheon, Paragon Bioservices and Samsung Biologics. These industry players focus on numerous organic and inorganic strategic such as acquisitions, mergers and novel product development to capitalize on market opportunities and maintain financial stability.
 

For instance, in May 2016, GE Healthcare partnered with JHL Biotech, a biopharmaceutical company that started its production facility in China. This partnership allowed JHL to use the KUBio manufacturing solution of GE Healthcare to manufacture monoclonal antibodies and biosimilars. This strategy enabled the company to strengthen its cell line development market portfolio and broaden existing customer base.
 

Explore More on Related Topics:

We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. More info X